The next-generation FARASTAR™ cardiac pulsed electric field ablation system manufactured by Boston Scientific at its Lingang plant in Shanghai was officially approved by the State Drug Administration. FARASTAR™ is the core energy generation device of Boston Scientific's FARAPULSE™ pulsed electric field ablation platform. It is used for atrial fibrillation treatment. The currently approved domestic FARASTAR™ uses the world's latest generation equipment platform and has a more complete safety design and stronger platform compatibility, such as supporting multiple types of catheter solutions.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.